Isabel Britsch
Overview
Explore the profile of Isabel Britsch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
42
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ploeg E, Samplonius D, Xiong X, Ke X, Hendriks M, Britsch I, et al.
J Immunother Cancer
. 2023 Sep;
11(9).
PMID: 37734877
Background: CD73 is an ecto-enzyme that is involved in the conversion of pro-inflammatory extracellular ATP (eATP) excreted by cancer cells under stress to anti-inflammatory adenosine (ADO). A broad variety of...
2.
Britsch I, van Wijngaarden A, Helfrich W
Cancers (Basel)
. 2023 Aug;
15(15).
PMID: 37568582
Infection with cytomegalovirus (CMV) is highly prevalent in the general population and largely controlled by CD8 T cells. Intriguingly, anti-CMV T cells accumulate over time to extraordinarily high numbers, are...
3.
Ploeg E, Britsch I, van Wijngaarden A, Ke X, Hendriks M, Samplonius D, et al.
Cancers (Basel)
. 2023 Jul;
15(14).
PMID: 37509310
PD-1/PD-L1-inhibiting antibodies have shown disappointing efficacy in patients with refractory ovarian cancer (OC). Apparently, OC cells exploit nonoverlapping immunosuppressive mechanisms to evade the immune system. In this respect, the CD73-adenosine...
4.
Britsch I, van Wijngaarden A, Ke X, Hendriks M, Samplonius D, Ploeg E, et al.
Oncoimmunology
. 2023 May;
12(1):2207868.
PMID: 37180637
Typically, anticancer CD8 T cells occur at low frequencies and become increasingly impaired in the tumor micro environment. In contrast, antiviral CD8 T cells display a much higher polyclonality, frequency,...
5.
Hendriks M, Britsch I, Ke X, van Wijngarden A, Samplonius D, Ploeg E, et al.
Oncoimmunology
. 2021 Dec;
10(1):2005344.
PMID: 34858730
Cancer cells exploit CD47 overexpression to inhibit phagocytic elimination and neoantigen processing via the myeloid CD47-SIRPα axis and thereby indirectly evade adaptive T cell immunity. Here, we report on a...
6.
Ploeg E, Ke X, Britsch I, Hendriks M, van der Zant F, Kruijff S, et al.
Cancer Lett
. 2021 Aug;
521:109-118.
PMID: 34464670
Tumor-derived extracellular vesicles (EVs) carry potent immunosuppressive factors that affect the antitumor activities of immune cells. A significant part of the immunoinhibitory activity of EVs is attributable to CD73, a...
7.
Hendriks M, Ploeg E, Koopmans I, Britsch I, Ke X, Samplonius D, et al.
Oncoimmunology
. 2020 Dec;
9(1):1824323.
PMID: 33299654
Cancer cells overexpress CD47 to subvert phagocytic elimination and evade immunogenic processing of cancer antigens. Moreover, CD47 overexpression inhibits the antibody-dependent cellular phagocytosis (ADCP) and cytotoxicity (ADCC) activities of therapeutic...